Better Therapeutics (NASDAQ:BTTX – Get Free Report) will likely be announcing its resultson Thursday, November 12th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $6.58 million for the quarter.
Better Therapeutics Stock Performance
NASDAQ BTTX opened at $0.00 on Thursday. Better Therapeutics has a one year low of $0.00 and a one year high of $0.00. The firm has a market cap of $4,058.00, a PE ratio of -0.00 and a beta of 0.90.
About Better Therapeutics
Better Therapeutics was a digital therapeutics company focused on developing prescription software designed to address chronic metabolic and cardiometabolic conditions. Its approach combined behavioral therapy, personalized digital coaching and clinical content delivered through software intended for use alongside standard medical care.
The company’s lead product, AspyreRx, formerly known as BT-001, was authorized by the U.S. Food and Drug Administration in 2023 as a prescription digital therapeutic for adults with type 2 diabetes.
Further Reading
- Five stocks we like better than Better Therapeutics
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
